Topography of the human papillomavirus minor capsid protein L2 during vesicular trafficking of infectious entry

Journal of Virology

Volumn 89, Issue 20, 2015, Pages 10442-10452

  DiGiuseppe, Stephen ^a   Keiffer, Timothy R ^a   Bienkowska Haba, Malgorzata ^a   Luszczek, Wioleta ^a   Guion, Lucile G M ^a   Müller, Martin ^b   Sapp, Martin ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN L2; DIGITONIN; EPITOPE; TRYPSIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; CAPSID PROTEIN; L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; L2 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN;

AMINO TERMINAL SEQUENCE; ANTIGEN RECOGNITION; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; CYTOSOL; ENDOPLASMIC RETICULUM; ENDOSOME; ENZYME DEGRADATION; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; TRANS GOLGI NETWORK; VIRUS CELL INTERACTION; VIRUS ENTRY; CHEMISTRY; DRUG EFFECTS; HEK293 CELL LINE; HELA CELL LINE; HOST PATHOGEN INTERACTION; HUMAN; INTRACELLULAR MEMBRANE; KERATINOCYTE; METABOLISM; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN TRANSPORT; TRANSFORMED CELL LINE; VIRION; VIROLOGY; VIRUS CAPSID;

CAPSID; CAPSID PROTEINS; CELL LINE, TRANSFORMED; CELL MEMBRANE PERMEABILITY; DIGITONIN; ENDOSOMES; HEK293 CELLS; HELA CELLS; HOST-PATHOGEN INTERACTIONS; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; INTRACELLULAR MEMBRANES; KERATINOCYTES; ONCOGENE PROTEINS, VIRAL; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN TRANSPORT; PROTEOLYSIS; TRYPSIN; VIRION; VIRUS INTERNALIZATION;

EID: 84942154619     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01588-15     Document Type: Article

References (64)

1. Crow JM. 2012. HPV: the global burden. Nature 488:S2-S3. http://dx.doi.org/10.1038/488S2a.
2. Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, Vignat J, Ferlay J, Bray F, Plummer M, Franceschi S. 2012. Global burden of human papillomavirus and related diseases. Vaccine 30(Suppl 5):F12-F23. http://dx.doi.org/10.1016/j.vaccine.2012.07.055.
3. Buck CB, Thompson CD, Pang YY, Lowy DR, Schiller JT. 2005. Maturation of papillomavirus capsids. J Virol 79:2839-2846. http://dx.doi.org/10.1128/JVI.79.5.2839-2846.2005.
4. Finch JT, Klug A. 1965. The structure of viruses of the papillomapolyoma type 3. Structure of rabbit papilloma virus, with an appendix on the topography of contrast in negative-staining for electron-microscopy. J Mol Biol 13:1-12.
5. Buck CB, Cheng N, Thompson CD, Lowy DR, Steven AC, Schiller JT, Trus BL. 2008. Arrangement of L2 within the papillomavirus capsid. J Virol 82:5190-5197. http://dx.doi.org/10.1128/JVI.02726-07.
6. Modis Y, Trus BL, Harrison SC. 2002. Atomic model of the papillomavirus capsid. EMBO J 21:4754-4762. http://dx.doi.org/10.1093/emboj/cdf494.
7. Buck CB, Pastrana DV, Lowy DR, Schiller JT. 2005. Generation of HPV pseudovirions using transfection and their use in neutralization assays. Methods Mol Med 119:445-462.
8. Buck CB, Pastrana DV, Lowy DR, Schiller JT. 2004. Efficient intracellular assembly of papillomaviral vectors. J Virol 78:751-757. http://dx.doi.org/10.1128/JVI.78.2.751-757.2004.
9. Unckell F, Streeck RE, Sapp M. 1997. Generation and neutralization of pseudovirions of human papillomavirus type 33. J Virol 71:2934-2939.
10. Knappe M, Bodevin S, Selinka HC, Spillmann D, Streeck RE, Chen XS, Lindahl U, Sapp M. 2007. Surface-exposed amino acid residues of HPV16 L1 protein mediating interaction with cell surface heparan sulfate. J Biol Chem 282:27913-27922. http://dx.doi.org/10.1074/jbc.M705127200.
11. Giroglou T, Florin L, Schafer F, Streeck RE, Sapp M. 2001. Human papillomavirus infection requires cell surface heparan sulfate. J Virol 75: 1565-1570. http://dx.doi.org/10.1128/JVI.75.3.1565-1570.2001.
12. Joyce JG, Tung JS, Przysiecki CT, Cook JC, Lehman ED, Sands JA, Jansen KU, Keller PM. 1999. The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes. J Biol Chem 274:5810-5822. http://dx.doi.org/10.1074/jbc.274.9.5810.
13. Selinka HC, Florin L, Patel HD, Freitag K, Schmidtke M, Makarov VA, Sapp M. 2007. Inhibition of transfer to secondary receptors by heparan sulfate-binding drug or antibody induces noninfectious uptake of human papillomavirus. J Virol 81:10970-10980. http://dx.doi.org/10.1128/JVI.00998-07.
14. Culp TD, Budgeon LR, Christensen ND. 2006. Human papillomaviruses bind a basal extracellular matrix component secreted by keratinocytes which is distinct from a membrane-associated receptor. Virology 347: 147-159. http://dx.doi.org/10.1016/j.virol.2005.11.025.
15. Bienkowska-Haba M, Patel HD, Sapp M. 2009. Target cell cyclophilins facilitate human papillomavirus type 16 infection. PLoS Pathog 5:e1000524. http://dx.doi.org/10.1371/journal.ppat.1000524.
16. Bienkowska-Haba M, Williams C, Kim SM, Garcea RL, Sapp M. 2012. Cyclophilins facilitate dissociation of the human papillomavirus type 16 capsid protein L1 from the L2/DNA complex following virus entry. J Virol 86:9875-9887. http://dx.doi.org/10.1128/JVI.00980-12.
17. Richards KF, Bienkowska-Haba M, Dasgupta J, Chen XS, Sapp M. 2013. Multiple heparan sulfate binding site engagements are required for the infectious entry of human papillomavirus type 16. J Virol 87:11426-11437. http://dx.doi.org/10.1128/JVI.01721-13.
18. Richards RM, Lowy DR, Schiller JT, Day PM. 2006. Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection. Proc Natl Acad Sci U S A 103:1522-1527. http://dx.doi.org/10.1073/pnas.0508815103.
19. Day PM, Schiller JT. 2009. The role of furin in papillomavirus infection. Future Microbiol 4:1255-1262. http://dx.doi.org/10.2217/fmb.09.86.
20. Schelhaas M, Shah B, Holzer M, Blattmann P, Kuhling L, Day PM, Schiller JT, Helenius A. 2012. Entry of human papillomavirus type 16 by actin-dependent, clathrin-and lipid raft-independent endocytosis. PLoS Pathog 8:e1002657. http://dx.doi.org/10.1371/journal.ppat.1002657.
21. Spoden G, Freitag K, Husmann M, Boller K, Sapp M, Lambert C, Florin L. 2008. Clathrin-and caveolin-independent entry of human papillomavirus type 16: involvement of tetraspanin-enriched microdomains (TEMs). PLoS One 3:e3313. http://dx.doi.org/10.1371/journal.pone.0003313.
22. Scheffer KD, Gawlitza A, Spoden GA, Zhang XA, Lambert C, Berditchevski F, Florin L. 2013. Tetraspanin CD151 mediates papillomavirus type 16 endocytosis. J Virol 87:3435-3446. http://dx.doi.org/10.1128/JVI.02906-12.
23. Scheffer KD, Berditchevski F, Florin L. 2014. The tetraspanin CD151 in papillomavirus infection. Viruses 6:893-908. http://dx.doi.org/10.3390/v6020893.
24. Abban CY, Meneses PI. 2010. Usage of heparan sulfate, integrins, and FAK in HPV16 infection. Virology 403:1-16. http://dx.doi.org/10.1016/j.virol.2010.04.007.
25. Yoon CS, Kim KD, Park SN, Cheong SW. 2001. α6 Integrin is the main receptor of human papillomavirus type 16 VLP. Biochem Biophys Res Commun 283:668-673. http://dx.doi.org/10.1006/bbrc.2001.4838.
26. Evander M, Frazer IH, Payne E, Qi YM, Hengst K, McMillan NA. 1997. Identification of the α6 integrin as a candidate receptor for papillomaviruses. J Virol 71:2449-2456.
27. Surviladze Z, Dziduszko A, Ozbun MA. 2012. Essential roles for soluble virion-associated heparan sulfonated proteoglycans and growth factors in human papillomavirus infections. PLoS Pathog 8:e1002519. http://dx.doi.org/10.1371/journal.ppat.1002519.
28. DiGiuseppe S, Bienkowska-Haba M, Hilbig L, Sapp M. 2014. The nuclear retention signal of HPV16 L2 protein is essential for incoming viral genome to transverse the trans-Golgi network. Virology 458-459: 93-105. http://dx.doi.org/10.1016/j.virol.2014.04.024.
29. Day PM, Thompson CD, Schowalter RM, Lowy DR, Schiller JT. 2013. Identification of a role for the trans-Golgi network in human papillomavirus 16 pseudovirus infection. J Virol 87:3862-3870. http://dx.doi.org/10.1128/JVI.03222-12.
30. Lipovsky A, Popa A, Pimienta G, Wyler M, Bhan A, Kuruvilla L, Guie MA, Poffenberger AC, Nelson CD, Atwood WJ, DiMaio D. 2013. Genome-wide siRNA screen identifies the retromer as a cellular entry factor for human papillomavirus. Proc Natl Acad Sci U S A 110:7452-7457. http://dx.doi.org/10.1073/pnas.1302164110.
31. Zhang W, Kazakov T, Popa A, DiMaio D. 2014. Vesicular trafficking of incoming human papillomavirus 16 to the Golgi apparatus and endoplasmic reticulum requires gamma-secretase activity. mBio 5(5):e01777-14.
32. Karanam B, Peng S, Li T, Buck C, Day PM, Roden RB. 2010. Papillomavirus infection requires gamma secretase. J Virol 84:10661-10670. http://dx.doi.org/10.1128/JVI.01081-10.
33. Huang HS, Buck CB, Lambert PF. 2010. Inhibition of gamma secretase blocks HPV infection. Virology 407:391-396. http://dx.doi.org/10.1016/j.virol.2010.09.002.
34. Day PM, Baker CC, Lowy DR, Schiller JT. 2004. Establishment of papillomavirus infection is enhanced by promyelocytic leukemia protein (PML) expression. Proc Natl Acad Sci U S A 101:14252-14257. http://dx.doi.org/10.1073/pnas.0404229101.
35. Aydin I, Weber S, Snijder B, Samperio Ventayol P, Kuhbacher A, Becker M, Day PM, Schiller JT, Kann M, Pelkmans L, Helenius A, Schelhaas M. 2014. Large scale RNAi reveals the requirement of nuclear envelope breakdown for nuclear import of human papillomaviruses. PLoS Pathog 10:e1004162. http://dx.doi.org/10.1371/journal.ppat.1004162.
36. Pyeon D, Pearce SM, Lank SM, Ahlquist P, Lambert PF. 2009. Establishment of human papillomavirus infection requires cell cycle progression. PLoS Pathog 5:e1000318. http://dx.doi.org/10.1371/journal.ppat.1000318.
37. Bronnimann MP, Chapman JA, Park CK, Campos SK. 2013. A transmembrane domain and GxxxG motifs within L2 are essential for papillomavirus infection. J Virol 87:464-473. http://dx.doi.org/10.1128/JVI.01539-12.
38. Kamper N, Day PM, Nowak T, Selinka HC, Florin L, Bolscher J, Hilbig L, Schiller JT, Sapp M. 2006. A membrane-destabilizing peptide in capsid protein L2 is required for egress of papillomavirus genomes from endosomes. J Virol 80:759-768. http://dx.doi.org/10.1128/JVI.80.2.759-768.2006.
39. Bossis I, Roden RBS, Gambhira R, Yang R, Tagaya M, Howley PM, Meneses PI. 2005. Interaction of tSNARE syntaxin 18 with the papillomavirus minor capsid protein mediates infection. J Virol 79:6723-6731. http://dx.doi.org/10.1128/JVI.79.11.6723-6731.2005.
40. Bergant Marusic M, Ozbun MA, Campos SK, Myers MP, Banks L. 2012. Human papillomavirus L2 facilitates viral escape from late endosomes via sorting nexin 17. Traffic 13:455-467. http://dx.doi.org/10.1111/j.1600-0854.2011.01320.x.
41. Bergant M, Banks L. 2013. SNX17 facilitates infection with diverse papillomavirus types. J Virol 87:1270-1273. http://dx.doi.org/10.1128/JVI.01991-12.
42. Florin L, Becker KA, Lambert C, Nowak T, Sapp C, Strand D, Streeck RE, Sapp M. 2006. Identification of a dynein interacting domain in the papillomavirus minor capsid protein l2. J Virol 80:6691-6696. http://dx.doi.org/10.1128/JVI.00057-06.
43. Schneider MA, Spoden GA, Florin L, Lambert C. 2011. Identification of the dynein light chains required for human papillomavirus infection. Cell Microbiol 13:32-46. http://dx.doi.org/10.1111/j.1462-5822.2010.01515.x.
44. Popa A, Zhang W, Harrison MS, Goodner K, Kazakov T, Goodwin EC, Lipovsky A, Burd CG, DiMaio D. 2015. Direct binding of retromer to human papillomavirus type 16 minor capsid protein L2 mediates endosome exit during viral infection. PLoS Pathog 11:e1004699. http://dx.doi.org/10.1371/journal.ppat.1004699.
45. Leder C, Kleinschmidt JA, Wiethe C, Muller M. 2001. Enhancement of capsid gene expression: preparing the human papillomavirus type 16 major structural gene L1 for DNA vaccination purposes. J Virol 75:9201-9209. http://dx.doi.org/10.1128/JVI.75.19.9201-9209.2001.
46. Volpers C, Sapp M, Snijders PJF, Walboomers JMM, Streeck RE. 1995. Conformational and linear epitopes on virus-like particles of human papillomavirus type-33 identified by monoclonal-antibodies to the minor capsid protein L2. J Gen Virol 76:2661-2667. http://dx.doi.org/10.1099/0022-1317-76-11-2661.
47. Ishii Y, Tanaka K, Kondo K, Takeuchi T, Mori S, Kanda T. 2010. Inhibition of nuclear entry of HPV16 pseudovirus-packaged DNA by an anti-HPV16 L2 neutralizing antibody. Virology 406:181-188. http://dx.doi.org/10.1016/j.virol.2010.07.019.
48. Sapp M, Kraus U, Volpers C, Snijders PJ, Walboomers JM, Streeck RE. 1994. Analysis of type-restricted and cross-reactive epitopes on virus-like particles of human papillomavirus type 33 and in infected tissues using monoclonal antibodies to the major capsid protein. J Gen Virol 75:3375-3383. http://dx.doi.org/10.1099/0022-1317-75-12-3375.
49. Rubio I, Seitz H, Canali E, Sehr P, Bolchi A, Tommasino M, Ottonello S, Muller M. 2011. The N-terminal region of the human papillomavirus L2 protein contains overlapping binding sites for neutralizing, crossneutralizing and non-neutralizing antibodies. Virology 409:348-359. http://dx.doi.org/10.1016/j.virol.2010.10.017.
50. Becker KA, Florin L, Sapp C, Maul GG, Sapp M. 2004. Nuclear localization but not PML protein is required for incorporation of the papillomavirus minor capsid protein L2 into virus-like particles. J Virol 78:1121-1128. http://dx.doi.org/10.1128/JVI.78.3.1121-1128.2004.
51. Schulz I. 1990. Permeabilizing cells: some methods and applications for the study of intracellular processes. Methods Enzymol 192:280-300. http://dx.doi.org/10.1016/0076-6879(90)92077-Q.
52. Krawczyk E, Suprynowicz FA, Sudarshan SR, Schlegel R. 2010. Membrane orientation of the human papillomavirus type 16 E5 oncoprotein. J Virol 84:1696-1703. http://dx.doi.org/10.1128/JVI.01968-09.
53. Labay V, Weichert RM, Makishima T, Griffith AJ. 2010. Topology of transmembrane channel-like gene 1 protein. Biochemistry 49:8592-8598. http://dx.doi.org/10.1021/bi1004377.
54. Bayer N, Schober D, Prchla E, Murphy RF, Blaas D, Fuchs R. 1998. Effect of bafilomycin A1 and nocodazole on endocytic transport in HeLa cells: implications for viral uncoating and infection. J Virol 72:9645-9655.
55. Selinka HC, Giroglou T, Sapp M. 2002. Analysis of the infectious entry pathway of human papillomavirus type 33 pseudovirions. Virology 299: 279-287. http://dx.doi.org/10.1006/viro.2001.1493.
56. Engel S, Heger T, Mancini R, Herzog F, Kartenbeck J, Hayer A, Helenius A. 2011. Role of endosomes in simian virus 40 entry and infection. J Virol 85:4198-4211. http://dx.doi.org/10.1128/JVI.02179-10.
57. Clarke MS, McNeil PL. 1992. Syringe loading introduces macromolecules into living mammalian cell cytosol. J Cell Sci 102:533-541.
58. Kyte J, Doolittle RF. 1982. A simple method for displaying the hydropathic character of a protein. J Mol Biol 157:105-132. http://dx.doi.org/10.1016/0022-2836(82)90515-0.
59. Sharpe JC, London E. 1999. Diphtheria toxin forms pores of different sizes depending on its concentration in membranes: probable relationship to oligomerization. J Membr Biol 171:209-221. http://dx.doi.org/10.1007/s002329900572.
60. Zalman LS, Wisnieski BJ. 1984. Mechanism of insertion of diphtheria toxin: peptide entry and pore size determinations. Proc Natl Acad Sci U S A 81:3341-3345. http://dx.doi.org/10.1073/pnas.81.11.3341.
61. Bilkova E, Forstova J, Abrahamyan L. 2014. Coat as a dagger: the use of capsid proteins to perforate membranes during non-enveloped DNA viruses trafficking. Viruses 6:2899-2937. http://dx.doi.org/10.3390/v6072899.
62. Daniels R, Rusan NM, Wadsworth P, Hebert DN. 2006. SV40 VP2 and VP3 insertion into ER membranes is controlled by the capsid protein VP1: implications for DNA translocation out of the ER. Mol Cell 24:955-966. http://dx.doi.org/10.1016/j.molcel.2006.11.001.
63. Inoue T, Tsai B. 2011. A large and intact viral particle penetrates the endoplasmic reticulum membrane to reach the cytosol. PLoS Pathog 7:e1002037. http://dx.doi.org/10.1371/journal.ppat.1002037.
64. Rainey-Barger EK, Magnuson B, Tsai B. 2007. A chaperone-activated nonenveloped virus perforates the physiologically relevant endoplasmic reticulum membrane. J Virol 81:12996-13004. http://dx.doi.org/10.1128/JVI.01037-07.